NEW YORK (GenomeWeb News) – Danish bioinformatics firms CLC bio announced today a deal with Aros Applied Biotechnology for the use of CLC bio's enterprise platform for analyzing next-generation sequencing data.
The deal covers all steps from extraction, sample banking, and analysis to advanced bioinformatics using CLC bio's platform. Aros will now provide its customers the option to receive their data in CLC bio's format, including a time-limited license for CLC Genomics Workbench for assembly and downstream sequence analyses, CLC bio said.
Financial and other terms of the deal were not disclosed.
CLC bio and Aros are already part of a collaboration with other firms in a $5 million project for the large-scale sequence analysis of formalin-fixed, paraffin-embedded tissue samples.
Aros, based in Denmark, specializes on total genomics solutions and is GLP and GCP certified.